Advancing our innovative pipeline
to address unmet needs

Endocrinology

A key driver of our plan to build a leading, fully integrated biopharmaceutical company focused on improving patients’ lives is the advancement of our pipeline of endocrinology rare disease product candidates.

In this area of unmet need, we utilize our TransCon™ technology with well-characterized parent drugs to create new therapies with the potential for best-in-class efficacy, safety or convenience.

Our endocrinology pipeline includes multiple, independent product candidates in phase 2 and phase 3 clinical development. Consistent with our Vision 3×3, we plan to create further growth of our endocrinology rare disease pipeline through label expansion and by establishing global clinical reach for these programs, either directly or through partnerships.

You are about to access www.ascendispharma.us. The information on this website is intended for residents of the United States. Click below to confirm you are a citizen and/or resident of the United States.

Go

You are about to access www.ascendispharma.us. The information on this website is intended for residents of the United States. Click below to confirm you are a citizen and/or resident of the United States.

Go